For more information on CyPass® Micro-Stent, visit www.getcypass.com

Alcon Cypass Collection Collection (8 videos)

Replay
Cancel

Your 25-second video preview has ended.

to continue watching, please Log In or Register:


Log in / Register

2-Year COMPASS Trial Results

Channels: Glaucoma

Nathan Radcliffe, MD, gives an overview of the 2-year results from the COMPASS trial. The trial evaluates safety and efficacy of supraciliary microstenting for treating mild-to-moderate primary open-angle glaucoma in patients undergoing cataract surgery. Dr. Radcliffe discusses the design of the trial and compares outcomes of cataract surgery patients implanted with the CyPass Micro-Stent (Alcon) with patients who received cataract surgery alone.

SURGICAL PEARLS

Alcon Cypass

One CyPass® Micro-Stent is all it takes to deliver on the promise of MIGS

LEARN MORE

The CyPass® Micro-Stent System
for the Treatment of Primary
Open-Angle Glaucoma

WATCH ANIMATION

CyPass® Micro-Stent

READ SUPPLEMENT

©2017 Novartis 04/17 x US-CYP-17-E-0634(1)